Navigation Links
Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
Date:5/28/2009

WAYNE, N.J., EMERYVILLE, Calif. and MELVILLE, N.Y., May 28 /PRNewswire-FirstCall/ -- Bayer HealthCare LLC., Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche today announced the initiation of a Phase 3 trial examining Nexavar(R) (sorafenib) tablets in combination with Tarceva(R) (erlotinib) tablets as a potential new treatment option for patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer.

The SEARCH (Sorafenib and erlotinib, a randomized trial protocol for the treatment of patients with hepatocellular carcinoma) trial aims to further build on data from the Phase 3 SHARP trial, which demonstrated that Nexavar significantly extended overall survival in patients with unresectable liver cancer by 44 percent (HR=0.69; p-value=0.0006). Based on the strength of these data, Nexavar was approved for the treatment of patients with unresectable HCC in the United States and in Europe for the treatment of HCC. Nexavar is currently approved in more than 70 countries for the treatment of HCC, including China where more than half of all liver cancer cases worldwide occur each year.

"Nexavar is the only approved targeted therapy with efficacy and tolerability in liver cancer," said Dimitris Voliotis, MD, vice president, Nexavar Clinical Development, Bayer HealthCare Pharmaceuticals. "We look forward to seeing the potential of combining Nexavar with another effective cancer treatment, Tarceva, in treating this disease and further extending the lives of patients."

"This study will enable us to learn whether combining two oral targeted therapies, Nexavar and Tarceva, can improve survival in a disease that is difficult to trea
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.; OSI Pharmaceuticals; Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinsons Disease
2. The National Association of Boards of Pharmacy (NABP) Moves to Next Phase of Technician Recognition and Regulation
3. MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
4. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
5. National Medical Interpreter Certification Testing Enters Pilot Phase
6. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
7. Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting
8. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
9. InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
10. BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting
11. Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Padre Murphy's and Owner ... of Pro Player Health Alliance (PPHA). The PPHA's ... in getting everyone, including NFL greats, treated for obstructive sleep ... leading groups supporting the cause in the valley. The most ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 The Incredible ... Bodybuilder Ben Pakulski to increase lean muscle by up to ... has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an ... that it is a step-by-step, scientific diet formula that allows ...
(Date:1/22/2015)... 22, 2015 Blue Cross and Blue Shield ... exemplify what it means to “Live Fearless.” , ... to share their stories about how they or someone they ... others by living in the moment. By telling these types ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... ... everyone will carry their snacks while on the go. KUBBE is the first and ... hassle free. , ... 17, 2010 -- KUBBE is a trendy plastic utility buckle that allows people to carry ...
... , , ... ... ... ...
... ... ... ... ...
... in the March issue of Radiology , researchers from ... have determined that an imaging exam of the heart using ... much as 91 percent less radiation than standard helical CT ... in recent years, due to its diagnostic accuracy in assessing ...
... ... ... ... ...
... ... ... ... , ...
Cached Medicine News:Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 2Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 3Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 4Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 5Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 6Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 7Health News:Pew Report: Connecticut is a National Leader in Addressing Children's Dental Health 2Health News:Pew Report: Connecticut is a National Leader in Addressing Children's Dental Health 3Health News:Pew Report: Connecticut is a National Leader in Addressing Children's Dental Health 4Health News:Pew Report: Connecticut is a National Leader in Addressing Children's Dental Health 5Health News:Pew Report: Connecticut is a National Leader in Addressing Children's Dental Health 6Health News:Pew Report: Connecticut is a National Leader in Addressing Children's Dental Health 7Health News:New cardiac CT technology drastically reduces patient radiation exposure 2Health News:E-Cigarette Maker Green Smoke Tells FDA to Back Off! 2Health News:E-Cigarette Maker Green Smoke Tells FDA to Back Off! 3Health News:E-Cigarette Maker Green Smoke Tells FDA to Back Off! 4Health News:Healthcare Realty Trust Announces Fourth Quarter Results 2Health News:Healthcare Realty Trust Announces Fourth Quarter Results 3Health News:Healthcare Realty Trust Announces Fourth Quarter Results 4Health News:Healthcare Realty Trust Announces Fourth Quarter Results 5Health News:Healthcare Realty Trust Announces Fourth Quarter Results 6Health News:Healthcare Realty Trust Announces Fourth Quarter Results 7Health News:Healthcare Realty Trust Announces Fourth Quarter Results 8Health News:Healthcare Realty Trust Announces Fourth Quarter Results 9Health News:Healthcare Realty Trust Announces Fourth Quarter Results 10Health News:Healthcare Realty Trust Announces Fourth Quarter Results 11Health News:Healthcare Realty Trust Announces Fourth Quarter Results 12Health News:Healthcare Realty Trust Announces Fourth Quarter Results 13Health News:Healthcare Realty Trust Announces Fourth Quarter Results 14Health News:Healthcare Realty Trust Announces Fourth Quarter Results 15
(Date:1/23/2015)... MYERS, Fla. , Jan. 23, 2015  Today the ... of Novartis, Bexsero® for the prevention of serogroup ... 25. Bexsero and Pfizer,s vaccine Trumenba®, which received FDA ... helping prevent this devastating disease. "I ...
(Date:1/23/2015)... Iowa , Jan. 23, 2015  The Partnership to Fight Chronic ... health care leaders and a new study analyzing the ... The PFCD is a nationwide coalition working to educate policy makers ... released at the Capitol was focused on how the ...
(Date:1/23/2015)... 23, 2015 More than a third of reproductive-aged women ... with private insurance, filled a prescription for an opioid pain ... this week,s Morbidity and Mortality Weekly Report (MMWR). ... treat moderate to severe pain.  They are also found in ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... Feb. 17 The United States, fifth hand ... home to Massena, New York this week after ... of Kleinert Kutz and University of Louisville ... UofL hand surgeons performed the Hondusky,s hand transplant ...
... Sanofi Pasteur, the,vaccines division of sanofi-aventis Group (EURONEXT ... is sponsoring a phase II clinical study of a ... causes of,hospital-acquired infection in Europe and North America. , ... the United Kingdom is investigating the,safety and efficacy of ...
Cached Medicine Technology:Fifth U.S. Hand Transplant Patient Heads Home to NY 2Fifth U.S. Hand Transplant Patient Heads Home to NY 3Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile 2Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile 3Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile 4Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile 5
... catheter design was created to be ... still providing high suctioning efficiency. Our ... or 10 Fr) feature depth markings ... Our complete catheter line is available ...
Suction catheter with thumb valve, two eyes, whistle tip...
Tracheal Suction Latex Rubber Catheters - Thumb Control Valve...
Rubber bronchial coude catheter, X-ray opaque, one eye, whistle tip....
Medicine Products: